title: Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
abstract: A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.
authors.affiliation: From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany; and †Urological Center Bonn, Bonn, Germany.
authors.forename: Carl Diedrich
authors.initials: CD
authors.lastname: Schlenkhoff
authors.forename: Florian
authors.initials: F
authors.lastname: Gaertner
authors.forename: Markus
authors.initials: M
authors.lastname: Essler
authors.forename: Matthias
authors.initials: M
authors.lastname: Schmidt
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000188:drug therapy*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D057176:Compassionate Use Trials; D004151:Dipeptides / Q000627:therapeutic use*; D004492:Edetic Acid / Q000031:analogs & derivatives; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D009842:Oligopeptides; D000072078:Positron Emission Tomography Computed Tomography; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011868:Radioisotopes / Q000009:adverse effects; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D011883:Radium / Q000009:adverse effects; D013669:Technetium Tc 99m Medronate
chemical_list: C000610110:Pluvicto; D000970:Antineoplastic Agents; D004151:Dipeptides; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006573:Heterocyclic Compounds, 1-Ring; D009842:Oligopeptides; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D008187:Lutetium; D004492:Edetic Acid; D017430:Prostate-Specific Antigen; C581106:radium Ra 223 dichloride; D011883:Radium; D013669:Technetium Tc 99m Medronate